Carrum healthThe first digital healthcare company to connect employers and employees via a consumer-centric platform for better and more cost-effective healthcare with Centers of Excellence (COEs) has expanded its national reach Mayo Clinic, one of the best hospital systems in the country. Carrum Health patients have access to quality surgical care for the joints and spine at the Mayo Clinic locations in Jacksonville, Florida. Phoenix, Arizona; Rochester, Minnesota; and Scottsdale, Arizona.
Carrum Health, in partnership with COEs across the country, has built a regionalized network of providers that use a rigorous and proprietary quality methodology to assess clinical performance at both the facility and surgeon level. Carrum Health selects hospitals and surgical centers that are at or near the top in their areas of expertise and then connects them directly with patients in need of the best possible care.
Self-insured employers, including several Fortune 500 companies, leverage Carrum Health’s technology-based COE platform to help prevent fluctuations in the cost and quality of surgery and deliver a superior patient experience. The platform enables employers to have transparent and predictable surgery prices for an entire phase of care such as a hip or knee replacement, and works with providers to provide high quality and efficient care under a value-based care model. Employees and insured members of companies offering the benefits of Carrum Health surgery have better access to world-class care through world-class facilities such as the Mayo Clinic. Carrum Health patients often save thousands of dollars on their surgery by eliminating 100 percent copays and co-insurance.
Oregon Health & Science University (OHSU) will begin offering Bright.mdThe automated telemedicine platform SmartExam for patients in October as part of the University’s Virtual Care Hub.
“In response to the COVID-19 pandemic, OHSU has dramatically expanded its ability to provide healthcare through telemedicine,” said Mark Lovgren, interim VP of the OHSU’s Office of Digital Health. “This collaboration is another way to ensure that our patients have convenient and safe home access to the best possible health care.”
SmartExam’s pre-built clinical content, protocol-driven modules, scalability, and automation that streamline clinical workflows ensure that providers have the tools they need to deliver high quality evidence-based care to hundreds of people in minutes To provide diseases with poor visual acuity.
SmartExam guides patients through a dynamic online medical interview about their current symptoms, medical history and medication. The platform then automatically retrieves information from the patient’s EHR and presents everything to a reviewing provider in a diagram-enabled SOAP note. The provider will review the preliminary diagnosis and treatment plan and may either approve or adjust the plan, or escalate the patient to a higher level of treatment if the complexity of the condition warrants it.
Truvian Sciences, a healthcare company at the intersection of diagnostics and consumer technology, announced today that the US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the company’s Easy Check COVID-19 IgM / IgG antibody test . Truvian’s Easy Check test is manufactured on a large scale in a U.S. facility and is readily available to healthcare professionals.
Rigorously tested and validated by leading health professionals and scientific experts from the University of California at San Diego (UCSD) and the University of Chicago, the test exceeds current EUA requirements for current COVID-19 antibody tests with a sensitivity rate of 98.44 percent and a specificity of 98.9 percent. Additionally, the cross-reactivity assessment showed no cross-reactivity (0 percent) with HIV, influenza A and B, and multiple coronavirus strains. “Truvian’s Easy Check performed exceptionally well in our own studies as well as those conducted by independent laboratories with a robust set of samples,” said Jeff Hawkins, president and chief executive officer of Truvian Sciences. “With its consistent reproducibility, we are confident that our test solution, which is supported by the FDA’s EEA, will raise the bar for COVID-19 antibody testing.”
Medtech business NeuropaceThe company, which developed an FDA-cleared device neurostimulator for seizure prevention, raised $ 67 million in a funding round led by Accelmed Partners that included an unnamed strategic investor, Revelation Partners, Soleus Capital and the returning investors KCK Group and OrbiMed Advisors attended. The financing includes $ 33 million in new equity and $ 34 million in convertible bonds raised by current investors from a previous financing round. The device was approved in March of this year. Click here to read more.
Image: Akindo, Getty Images
Note: We are not the author of this content. For the Authentic and complete version,
Check its Original Source